Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rosiglitazone in Obese Insulin Resistant Subjects
NCT00197132Phase 3Completed
- Sponsor
- GSK
- Start
- Oct 2002
- Primary completion
- Aug 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of rosiglitazone in insulin resistance (IR) (2 arms), sponsored by GSK. Primary endpoint: Forearm blood flow. Started Oct 2002; status: completed.
02
Drugs
rosiglitazone
03
Conditions
insulin resistance (IR)
Beyond the preview
Go deeper on NCT00197132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00197132.